FIELD: medicine, pharmaceutics.
SUBSTANCE: group of invention refers to medicine and concerns a pharmaceutical composition, and a method of stimulating an immune response to Mycobacterium avium, subspecies paratuberculosis (MAP) in a mammal. The composition contains a recombinant polypeptide containing from N-terminal to C-terminal: a C-terminal fragment of MAP_3527 protein, an amino acid sequence of MAP_1519 protein, and then an N-terminal protein of MAP 3527 protein. The method involves administering the pharmaceutical composition in animals in the amounts sufficient to stimulate the immune response on MAP.
EFFECT: group of inventions provides either eliminating, or delaying the MAP proliferation over a period of infection.
18 cl, 3 ex, 31 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT, DIAGNOSTICS OR PREVENTION OF LEISHMANIASIS CAUSED BY VARIOUS TYPES OF PARASITES, EXCEPT THAT ONE USED TO PRODUCE HISTONES, WITH USING ALL OF FOUR HISTONES H2A, H2B, H3 AND H4, RECOVERED FROM LEISHMANIA INFANTUM WITH USING VECTOR CONTAINING NUCLEOTIDES CODING SPECIFIED HISTONES | 2004 |
|
RU2380710C2 |
| RECOMBINANT PROTEIN CARRYING HUMAN PAPILLOMA VIRUS EPITOPES, PROTEIN EMBEDDED ADENYLATECYCLASE OR ITS FRAGMENT, ITS THERAPEUTIC APPLICATION | 2005 |
|
RU2441022C2 |
| AGENTS AND METHODS OF TREATING HEPATITIS B VIRUS | 2017 |
|
RU2740802C2 |
| VACCINE AGAINST HERPES SIMPLEX VIRUS TYPE 2: COMPOSITIONS AND METHODS FOR TRIGGERING IMMUNE RESPONSE | 2010 |
|
RU2585961C9 |
| RECOMBINANT INFLUENZA VIRUS STRAINS EXPRESSING MYCOBACTERIAL PROTECTIVE ESAT-6 ANTIGEN AND USES THEREOF IN TUBERCULOSIS TREATMENT AND PROPHYLAXIS | 2005 |
|
RU2318872C2 |
| MYCOBACTERIUM TUBERCULOSIS VACCINE | 2009 |
|
RU2473365C1 |
| RECOMBINANT PLASMID pAg85A-CBD, Escherichia coli [pREP4, pAg85A-CBD] STRAIN, CHIMERIC PROTEIN Ag85A-CBD AND THEIR APPLICATION | 2010 |
|
RU2429292C1 |
| RECOMBINANT PLASMID, Escherichia coli STRAIN, CHIMERIC PROTEIN AND THEIR APPLICATION | 2010 |
|
RU2422525C1 |
| MUTANT POLYMERASES OF HEPATITIS B VIRUS | 2012 |
|
RU2625021C2 |
| PHARMACEUTICAL COMPOSITIONS FOR THERAPEUTIC APPLICATION | 2004 |
|
RU2362586C2 |
